- Receiving low-dose aspirin for >5 years was associated with a modest duration-dependent reduction in incident lung cancer risk, especially among the elderly and people without diabetes.
Why this matters
- Previous studies of the chemopreventive benefit of low-dose aspirin have produced conflicting results.
- 12,969,400 people aged 40-84 years from the Korean National Health Information Database.
- Follow-up was 63,787,432.9 person-years.
- Funding: None disclosed.
- 0.5% developed lung cancer.
- Compared with no use, low-dose aspirin use for >5 years was significantly associated with reduced lung cancer risk in a duration-dependent manner (5-6 years' use aHR, 0.96; 7-8 years' use aHR, 0.94; 9 years' use aHR, 0.89; P<.001>
- Long-term use of low-dose aspirin was significantly associated with reduced risk for lung cancer in:
- People ≥65 years (5-6 years' use aHR, 0.95; 7-8 years' use aHR, 0.93; 9 years' use aHR, 0.87; P<.001>
- People without diabetes (5-6 years' use aHR, 0.96; 7-8 years' use aHR, 0.94; 9 years' use aHR, 0.87; P<.001>
- Retrospective study with small effect size.